Abstract
Abstract
Background
The liver is the central organ for cholesterol homoeostasis, and its dysfunction might cause liver pathological alterations including hepatocellular carcinomas (HCCs). 3β-hydroxysteroid-Δ24 reductase (DHCR24), a crucial enzyme of cholesterol biosynthetic pathway, is involved in lipid rafts formation. Genkwadaphnin (GD) is a daphnane diterpene isolated from the flower buds of Daphne genkwa Siebold et Zuccarini (Thymelaeaceae).
Methods
We evaluated in vitro and in vivo effect of GD using HCC cells and BALB/c nude mice. Microarray assays were used to identify the differential genes by GD. DHCR24 expression and activity, cholesterol level, lipid rafts structure and the role of DHCR24 in human HCC specimens were tested by various molecular biology techniques.
Results
High expression of DHCR24 in human HCC specimens was correlated with poor clinical outcome. Interfering DHCR24 altered growth and migration of HCC cells. GD inhibited growth and metastasis of HCC cells both in vivo and in vitro. GD suppressed DHCR24 expression and activity, as well as DHCR24-mediated cholesterol biosynthesis and lipid rafts formation, then further inhibited HCC cell invasion and migration.
Conclusions
Our data suggest that DHCR24-mediated cholesterol metabolism might be an effective therapeutic strategy in HCC, and natural product GD might be a promising agent for HCC therapy.
Funder
the Scientific Research Projects of Hubei Health and Health Commission
National Natural Science Foundation of China
Natural Science Foundation of Liaoning Province
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 68, 394–424 (2018).
2. Aghemo, A. Update on HCC management and review of the New EASL Guidelines. Gastroenterol. Hepatol. (NY) 14, 384–386 (2018).
3. de Lope, C. R., Tremosini, S., Forner, A., Reig, M. & Bruix, J. Management of HCC. J. Hepatol. 56, 75–87 (2012).
4. Mao, K., Yan, Y., Zhang, J., Wang, J., Wang, R., Ling, X. et al. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: a propensity score matching study. Cancer Med. 7, 4475–4484 (2018).
5. De Matteis, S., Ragusa, A., Marisi, G., De Domenico, S., Casadei Gardini, A., Bonafe, M. et al. Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities. Oxid. Med. Cell Longev. 2018, e7512159 (2018).
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献